Kornimate/medical-research-clean huggingface dataset:
a nursing intervention program to improve therapeutic adherence in elderly people with acute myocardial infarction

Conditions: Medication Adherence; Myocardial Infarction

Summary: the objective of this study was to assess the impact of a nursing intervention on therapeutic adherence in elderly patients after acute myocardial infarction compared to a control group

a comprehensive geriatric assessment was performed during the first admission in all patients. patients were randomly allocated to a nursing intervention group or a usual care group. in patients from the intervention group, a nursing intervention programme was performed 3 months after admission, based on education, support and patient monitoring to improve therapeutic adherence and a 6 month phone call. the main outcome measured was therapeutic adherence at 12 months, as defined by a combination of adherence measurement tools (morisky-green and hayness-sacket scales, attendance at visits and withdrawal of medication from the pharmacy). therapeutic adherence was assessed by nurses blinded to the assignment group.

Eligibility criteria:
inclusion criteria: * patients with stemi aged 75 years or older underwent primary percutaneous coronary intervention (pci) exclusion criteria: * patients who refused to participate in the study * patients unable to perform geriatric assessment. * patients admitted to nursing homes or social health centres.

Keywords: elderly nursing
off-label use of ribavirin in management of mucocutaneous extrahepatic manifestations of hcv infection

Conditions: Hepatitis C; Lichen Planus; Vasculitis; Autoimmune Diseases

Summary: this study will be conducted on 30 patients with mucocutaneous complaints and documented hcv infection. the study will be done at tropical medicine department , tanta university. it will be conducted between june2014 and november 2014. the aim of the study is to assess efficacy of ribavirin in the management of mucocutaneous extrahepatic manifestations of hcv infection.

hepatitis c virus is a common cause of chronic liver disease worldwide and represent public health problem. the egyptian demographic health survey (edhs), a cross sectional survey including hepatitis c virus (hcv) biomarkers, was conducted in 2008 on a large nationally representative sample. it estimated hcv prevalence among the 15-59 years age group to be 14.7% . accordingly, egypt has the highest hcv prevalence in the world. although hcv is a hepatotropic virus, in some patients the primary manifestations of infection occur outside the liver. there is a growing body of evidence to support the idea that hcv can replicate efficiently in extrahepatic tissues including the peripheral blood mononuclear cells (pbmc). autoimmune manifestations are common in patients chronically infected by hcv . these manifestations can be dominant, whereas the hepatic disease can be quiescent or mild. more recently, there has been growing interest in the relationship between hcv and sjogren's syndrome (ss), rheumatoid arthritis (ra), and systemic lupus erythematosus (sle). of those , this article is interested in cutaneous and mucous membrane manifestations where many reports have shown that cutaneous manifestations are often the first signs of chronic hcv infection and these are indicated in 20-40% of the patients presenting to the dermatology clinics, therefore dermatologists must be aware of skin disorders associated with viral infection. the most commonly encountered dermatological manifestations of hcv infection includes mixed cryoglobulinemia (mc), porphyria cutanea tarda (pct), cutaneous and/or oral lichen planus (lp), urticaria, pruritus, thrombocytopenic purpura and cutaneous vasculitis. although majority of skin manifestations of chronic hcv infection represent the clinical impression of autoimmune phenomena, however, precise pathogenesis of these extra-hepatic complications is not well understood. the aim of the study is to assess efficacy of ribavirin in the management of mucocutaneous extrahepatic manifestations of hcv infection this study will be conducted on 30 patients with mucocutaneous complaints and documented hcv infection. the study will be done at tropical medicine department , tanta university. it will be conducted between june2014 and november 2014.

Eligibility criteria:
inclusion criteria: * patients with evidence of hcv infection and mucocutaneous complaint and contraindicated to have standard antiviral therapy. exclusion criteria: * hypersensitivity to ribavirin * pregnant \& lactating women * male partners of pregnant women
can urinary concentrations of timp2 and igfbp7 be used to predict early acute renal failure following cardiac arrest?

Conditions: Renal Failure; Heart Failure

Summary: transient renal insufficiency is frequently observed in the course of cardiovascular arrest. although elevation of creatinine is reversible in a large majority of cases, severe renal insufficiency is sometimes observed and is associated with a dark prognosis. any intervention that may limit the worsening of renal function may have an impact on patient mortality. there is currently no validated pharmacological treatment to limit the progression of ari or to accelerate its recovery. a major challenge then concerns the detection of the reversible character of renal damage. renal biomarkers have been little studied in the prediction of severe ari and mortality after cardiac arrest. the combination of timp2 (tissue inhibitor of metalloproteinase) and insulin-like growth factor binding protein (igfbp7) in urine showed good diagnostic performance in the early detection of the risk of developing acute renal failure within 12 hours. measured in the urine, the excretion of these two markers specifically reflects renal tubular lesions. moreover, their rate seems to be strongly correlated with the severity of the tubular lesions. thus, it can be reasonably assumed that their very early dosing in post-cardiac arrest could detect the presence and severity of renal tubular lesions. a threshold to be defined would discriminate patients at risk of developing an ari within 48 hours post acr and to distinguish between severe transient and severe persistent lesions beyond 72 hours.


Eligibility criteria:
inclusion criteria: * age over 18 years * cardio-circulatory arrest within 6 hours * person affiliated to a social security scheme exclusion criteria: * acute renal failure requiring urgent era in the opinion of the resuscitator anuria * chronic renal insufficiency stage 4-5 with a glomerular filtration rate estimated at less than 30 ml / min. * rapidly progressive renal disease (glomerulonephritis, hus, obstruction ...) renal insufficiency * probable glomerular involvement (nephritic syndrome, nephrotic syndrome, chronic glomerulonephritis) * pregnant or nursing women * patient under tutelage or curatorship or deprived of public right. * transplantation * subject involved in another search including an exclusion period still in progress at pre-inclusion
a text messaging (sms) intervention to improve adherence to stimulant medications in children with adhd

Conditions: Attention Deficit/Hyperactivity Disorder

Summary: this study will assess the efficacy of the text messaging (sms-based) disease management intervention for children with attention deficit/hyperactivity disorder (adhd) using the timeliness of stimulant prescription renewals over a 9-month period. parents of participants in the study will receive customized text messages once a day, sunday through friday, for a duration of 9 months. the text messages will include reminders to adhere to the individualized medication regimen, reminders to call their child's clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about adhd and its treatment.


Eligibility criteria:
inclusion criteria: * children 6-12 years of age of both sexes and their parent * a diagnosis of icd-10 or dsm 5 diagnosis of attention deficit/hyperactivity disorder including the following icd codes (f90 attention-deficit hyperactivity disorders; f90.0 attention-deficit hyperactivity disorder, predominantly inattentive type; f90.1 attention- deficit hyperactivity disorder, predominantly hyperactive type; f90.2 attention-deficit hyperactivity disorder, combined type;f90.8 attention-deficit hyperactivity disorder, other type; f90.9 attention-deficit hyperactivity disorder, unspecified type) and/or the following dsm 5 diagnoses (314.01, f90.2 attention-deficit/hyperactivity disorder, combined presentation; 314.01, f90.1 attention-deficit/hyperactivity disorder, predominantly hyperactive/impulsive presentation;314.00, f90.0 attention- deficit/hyperactivity disorder, predominantly inattentive presentation) * starting or currently on stimulant medication including (amphetamine/dextroamphetamine (adderall);dextroamphetamine (dexedrine, procentra, zenzedi, adderall xr); dexmethylphenidate (focalin, focalin xr); methylphenidate (ritalin, ritalin sr, metadate er, methylin er, concerta, daytrana, metadate cd, quillivant xr, ritalin la); amphetamine sulfate (evekeo); lisdexamfetamine (vyvanse)) * proficient in english * has a cellular phone with text messaging capabilities and is interested in and willing to receive free of charge text messages exclusion criteria: * investigator and his/her immediate family * unwilling/unable to comply with study procedures

Keywords: attention deficit/hyperactivity disorder adhd sms intervention
biomarkers of traumatic brain injury with tbit system

Conditions: Brain Injuries, Traumatic

Summary: a prospective, multi-center, non-randomized, pivotal study to assess the safety and efficacy of the tbit™ system to aid in patient evaluation, suspected of traumatic brain injury, as adjunct companion test to radiologic standard of care, cranial computerized tomography (cct).


Eligibility criteria:
inclusion criteria: * at least 18 years of age * presents to the emergency department with suspected traumatic brain injury * prescribed a non-contrast cct as part of routine emergency care within 24 hours from injury * blood sample collected for tbit™ system within 12 hours of injury * willing and able to provide informed consent or obtain consent from legal authorized representative (lar) exclusion criteria: * suspect of ischemic or hemorrhagic stroke with subsequent incidental trauma based on ed examination * subject suspect of need of craniotomy for the acute trauma for this event * external signs compatible with a depressed skull fracture based on ed exam * subject requiring administration of blood transfusion after injury and prior to study blood draw * subject for whom timing of injury is unable to be estimated within 1 hour of certainty * subject with a condition precluding entry into the ct scanner * subject who had neurodegenerative disease or other neurological disorder including dementia, parkinson's disease, multiple sclerosis, seizures, brain tumors, stroke or tia within the last 30 days, or history of neurosurgery * known or suspected to be pregnant * prisoner or under incarceration * participating in another clinical research study prior to this study completion

Keywords: brain injuries disease trauma nervous system wounds
study of ngm282 in subjects with functional constipation and healthy individuals

Conditions: Functional Constipation

Summary: the purpose of this study is to determine the effect of ngm282 on colonic transit, bile acid homeostasis, and fecal fat in subjects with functional constipation and healthy individuals.


Eligibility criteria:
inclusion criteria: * functional constipation confirmed by modified rome iii criteria or healthy volunteer exclusion criteria: * structural or metabolic diseases/conditions that affect the gi system * diagnosis of dyspepsia, ibs, or significant gastrointestinal symptoms
a comparative study of intrathecal dexmedetomidine and fentanyl as additives to bupivacaine in pott's fracture

Conditions: Post Operative Pain

Summary: the aim of this study is to compare the addition of intrathecal dexmedetomidine or fentanyl as adjuvants to hyperbaric bupivacaine in the onset and duration of sensory and motor block, and postoperative analgesia.

the aim of this study is to compare the addition of intrathecal dexmedetomidine or fentanyl as adjuvants to hyperbaric bupivacaine in the onset and duration of sensory and motor block, and postoperative analgesia. all patients will be assessed preoperatively by careful history taking, full physical examination, and laboratory evaluation. an informed written consent will be taken from every patient just before the surgery. on arrival to the operating room, baseline parameters such as ecg, mean arterial blood pressure, heart rate, and oxygen saturation will be recorded. intravenous line will be inserted and iv ringer's solution will be started, 500ml bolus will be given as a preload over 20 min before performing spinal anesthesia and maintenance volume of 10ml\\kg. for each group, patients will be put in sitting position, lumbar puncture will be performed under complete aseptic precautions, local anesthesia will be administered by infiltration of the skin and subcutaneous tissues with 3-5 ml lidocaine 1% at l3-l4 and a 25-g needle will be used. * group 1: (control group) (20 cases): patients will receive 3 ml (15mg) of 0.5% hyperbaric bupivacaine+0.5 ml of normal saline intrathecally. * group 2: (fentanyl group) (20 cases): patients will receive 3 ml (15 mg) of 0.5% hyperbaric bupivacaine+0.5 ml (25μg) of fentanyl intrathecally. * group 3: (dexmedetomidine group) (20 cases): patients will receive 3 ml (15 mg) of 0.5% hyperbaric bupivacaine+0.5 ml (5μg) of diluted dexmedetomidine intrathecally.

Eligibility criteria:
inclusion criteria: * • asa i or asa ii patients scheduled for pott's, of either sex. * age 21-55 years. * height 160 to 190 cm. * bmi ≤40. * procedure duration ≤ 90 minutes exclusion criteria: * • patients with known neurologic and psychiatric illness. * contraindications for spinal anesthesia as patient refusal, bleeding or coagulation test abnormalities, local skin infection at spinal lumbar region, raised intracranial pressure and hypovolemia. * spine abnormalities. * systemic disorders like hematological, respiratory, cardiac, renal or hepatic insufficiency. * allergy to any of the drugs used in the study. * women with pregnancy and lactation
endo-epicardial vs endocardial-only catheter ablation of ventricular tachycardia in patients with ischemic cardiomyopathy (epic-vt)

Conditions: Ischemic Cardiomyopathy; Catheter Ablation of Ventricular Tachycardia

Summary: radiofrequency ablation of ventricular tachycardias (vts) is the gold standard treatment of refractory vts in patients with ischaemic heart disease. in this setting, ablation is usually performed endocardially. however, even after a procedural success there is a high risk of recurrence, particularly due to the inability to create transmural lesions. indeed, only the endocardium of the lv has been ablated, while a significant part of the arrhythmia substrate may be located on the other side of the myocardial thickness, on the epicardial side of the lv. first described in 1996, epicardial ablation, performed via a percutaneous subxyphoid approach, has since undergone considerable development. electrophysiologists often use a double endo- and epicardial approach as first line therapy for the ablation of vts complicating myocarditis or arrhythmogenic dysplasia of the right ventricle, where the substrate is most often epicardial. for vt in ischaemic heart disease, electrophysiologists perform endocardial ablation, and often perform epicardial ablation only after several endocardial failures. several observational studies suggest that a combined endo- and epicardial approach as first line therapy is associated with a reduced risk of vt recurrence. since recurrent vt in patients with ischaemic heart disease as a prognostic impact in terms of morbidity and mortality, it appears essential to optimise rhythm management by ablation, by offering a combined approach from the as first approach to reduce the risk of recurrences. the aim of our prospective, multicentre, controlled, randomized study is therefore to compare the rate of vt recurrence after ablation performed as first line therapy either by endocardial approach alone or by combined endo-epicardial approach.


Eligibility criteria:
inclusion criteria: 1. patients over 18 years of age 2. 1st radiofrequency ablation of vt complicating ischaemic heart disease 3. patients with an icd and remote monitoring 4. having, for women of childbearing age, effective contraception until discharge from hospital 5. have given their free and informed consent in writing 6. are affiliated to or have health insurance exclusion criteria: 1. history of cardiac surgery compromising the epicardial approach (coronary artery bypas s grafting, valve replacements, or other surgeries that may have caused pericardial adhesions) 2. anticoagulant therapy that cannot be temporarily discontinued 3. double antiplatelet therapy that cannot be temporarily replaced by single antiplatelet therapy 4. history of pericarditis 5. previous thoracic radiotherapy 6. contraindication to general anaesthesia 7. pregnant or breastfeeding woman 8. history of heparin-induced thrombocytopenia type 2 (as injection is required during the procedure) 9. person under legal protection (safeguard of justice, curatorship, guardianship), deprived of liberty, or unable to express consent

Keywords: ischemic cardiomyopathy
race-2l: real-world assessment of clinical practice and outcomes in non-squamous nsclc after failure of platinum-based chemotherapy in brazil

Conditions: Non-squamous Non-Small Cell Lung Cancer

Summary: the study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a/m non-squamous nsclc with or without aga and received at least 1 line of systemic treatment after failing ptc between january 2017 and december 2022.

the study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with advanced/metastaic non-squamous nsclc with or without aga and who have failed platinum-based chemotherapy and immunotherapy (for patients without aga) or platinum-based chemotherapy and at least 1 line of targeted therapy (for patients with aga). the study will be conducted on one cohort of patients regardless their aga status. the study index date will be defined as first dose of any agent after ptc, with specific treatments received for aga and non-aga patients in the preindex period. we will also conduct a subgroup analysis on nsclc pre-defined subtypes (sample size permitting): egfr mutant, alk translocation, ros1 translocation, met1 mutant, her-2 mutant, braf mutant, pan-wild-type pd-l1 \>50%.

Eligibility criteria:
inclusion criteria * confirmed diagnosis of patients with non-squamous nsclc stage iiib/iiic not eligible for curative-intent therapies or stage iv/m1 (a/m nsclc) with or without actionable genomic mutations (i.e., egfr, alk, ros1, ntrk, braf, met exon 14 skipping, ret, her-2) * aged at least 18 years at first diagnosis of a/m nsclc * for the aga subgroup, having received platinum-based chemotherapy, having received at least one target approved therapy. * for the non_aga subgroup,should have received either sequential or concurrent use of ici and ptc) * patient must have received at least line of therapy of an active agent after failing ptc. exclusion criteria * patients with evidence of other primary malignancies (apart from basal cell carcinoma and melanoma) within 1 year prior to the index date will be excluded from both the study cohorts. * patients who participated in an investigational clinical trial for the treatment of any cancer, including nsclc, or any early access program from 2018 onward.
antabuse in severe alcoholism: an open controlled study

Conditions: Alcoholism

Summary: newly detoxified alcoholics (n=60) are randomised to either antabuse (disulfiram) treatment or the control group for a total of 6 months.all patients will receive cognitive behavioural treatment in groups. the hypothesis to be tested is that more of the patients who receive antabuse (disulfiram) will be alcohol free during the 6 months treatment period compared to the control group. the trial is open.


Eligibility criteria:
inclusion criteria: * alcoholism * living in the departments catchment area exclusion criteria: * pregnancy * schizophrenia * bipolar disorder * other substance abuse * dementia * anorexia

Keywords: alcoholism antabuse disulfiram abstinence cognitive behavioural therapy
prospective evaluation of the non-invasive icp headsense monitor in tbi patients undergoing invasive icp monitoring

Conditions: Brain Injuries; Intracranial Hypertension

Summary: patients with severe traumatic brain injury (tbi) are admitted to the intensive care unit (icu). under certain condition (such as a impaired consciousness) the intracranial pressure (icp) is measured. an increase in the intracranial pressure might suggest secondary neurological deterioration and is considered an alarming symptom. current practice is to insert an invasive monitor through a burr hole in the skull with the risk of bleeding and infection. using a new type of icp monitor (headsense) it is possible to measure icp non-invasively through an acoustic signal.

in this pilot study, the investigators will prospectively collect relevant clinical data on 15 tbi patients with an inserted invasive icp monitor. each enrolled patient will be monitored in parallel to the invasive icp monitor with the headsense's icp monitor. subjects who meet the study's inclusion and exclusion criteria will be enrolled in the study. family members will be asked for consent. the patient's clinical condition will be recorded in a case record form (crf). once the patient is inclined with his upper body 30 degrees to the bed and the invasive icp monitor displays the pressure values, the clinical procedure can begin. once the headsense's monitor is calibrated it is connected to the front end that is placed on the patient's ears. each recording session will be ½-48 hours long, depending on the patient's clinical condition. in case the icp monitor is still inserted to the patient's brain in the following day, recording sessions will continue until the icp monitor is removed. after the study, the patient's ears will be examined for internal ear infection or irritation that might be caused by the ear buds. patient adverse events will be documented on the case report forms in case they occurred, and the family or advocate of the patient will be informed. in case of clinical relevant adverse event, appropriate clinical action will be taken. as the procedure does not affect the patient management, there is no need to provide any specific medical care related to the trial. patients will receive the relevant clinical care related to their clinical management, without any consideration to their participation in the trial. once the data collection is done, results will be analyzed by comparing icp readings from both devices. the end point of the study is to collect at least half an hour of icp monitoring for each participant.

Eligibility criteria:
inclusion criteria: * have an invasive icp monitoring * male or female in the age range of 18 years and older exclusion criteria: * local infection in the ear. * pregnant/lactating women

Keywords: brain injuries noninvasive monitoring intracranial pressure